Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 22 November 2016 | By Zachary Brennan
Beginning next November, pharmaceutical companies will be required to mark their products with a National Drug Code (NDC), serial number, lot number and expiration date in both machine-readable and human-readable format thanks to the Drug Supply Chain Security Act (DSCSA) of 2013.
In preparation for that deadline and others over the next seven years, a diverse group of 44 companies – from manufacturers to wholesalers to solution providers – came together to develop an updated GS1 guideline, released 7 November, on the use of GS1's Electronic Product Code Information Services (EPCIS) for lot-level management and item-level traceability of pharmaceuticals.
Peter Sturtevant, senior director of industry development at GS1 US, told Focus that he’s heard anecdotally that 12-15% of drugs have such 2D matrix barcodes already, though companies are currently ramping up work.
Intended to keep the pharmaceutical supply chain more secure and further protect patients, the DSCSA mandates the creation of an electronic, interoperable system to track and trace certain prescription drugs distributed in the US. At least 40 other countries use or are in various stages of developing such serialization systems, including Turkey, China, Argentina, Brazil and the EU, though none are the same and there are no current plans for worldwide harmonization.
DSCSA, which will be implemented over 10 years, requires the creation of certain reports to track the progress of how the legislation is helping further protect the pharmaceutical supply chain and companies are transitioning their systems and preparing for the various requirements in three phases (though the DSCSA law sets 2023 as the final required deadline for serialized pharmaceutical traceability):
The 600+ page GS1 guideline and compendia offer information and examples to the wider industry looking to meet the law's obligations and record each shipping event and data element needed to support serialization, pedigree and track and trace. The guideline also shows industry how to apply the standards to their own businesses.
Sturtevant told Focus that right now, one of the biggest questions is on the idea of aggregation.
Aggregation allows for companies to track the relationships between the various parts of packages in a shipment of pharmaceuticals, essentially allowing a receiver to scan one code and understand what is in each part.
“The majority are probably preferring aggregation,” Sturtevant said, noting that some of the largest wholesale distributors have said it’s a requirement that companies use aggregation, “but it’s still a point of contention out there.”
The US Food and Drug Administration also is expected to release several guidance documents related to the DSCSA and Sturtevant said industry is moving forward to meet next year's requirements and do not expect to need any additional time to meet them, though FDA has had to delay implementation deadlines in the past.
In terms of the changes made in the release of version 1.2 of the guideline as compared to 1.1, the guideline notes:
Sturtevant told Focus there are 16 different exceptions that have been evaluated, including cases where there is damage to product or failures on the IT side.
GS1 US DSCSA Implementation Suite
Tags: GS1, traceability, pharmaceutical track and trace, serialization, DSCSA
Regulatory Focus newsletters
All the biggest regulatory news and happenings.